CRA assessed commercial efforts to develop and commercialize a MS drug with respect to obligations stemming from the acquisition of Genzyme Corporation by Sanofi-Aventis following shareholder concerns. In particular, CRA assessed the development strategy for the drug, including an assessment of its launch market access strategy and pricing strategy in various countries in the context of the drug’s attributes and existing available treatments. Further, CRA assessed Plaintiff theories of appropriate commercialization in connection with the achievement of contingent milestones associated with commercial sales.
Managing private markets risk for US banks
The Bank of England’s (BoE’s) second System-Wide Exploratory Scenario (SWES) tests how stress in private equity (PE) and private credit (PC) could transmit...